ROS-triggerable dual nanocoated probiotics for inflammatory bowel disease treatment
Inflammatory bowel disease (IBD), an immune-mediated chronic gastrointestinal disease, is difficult to treat because its specific pathogenic mechanisms are currently unclear, and its recurrence rate is high. Probiotic therapies have been used to treat IBD; however, challenges, including poor digesti...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Taylor & Francis Group
2026-12-01
|
| Sraith: | Drug Delivery |
| Ábhair: | |
| Rochtain ar líne: | https://www.tandfonline.com/doi/10.1080/10717544.2026.2630460 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|